PHAXIAM TX overview

Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1 ), a biopharmaceutical company (“PHAXIAM” or “the Company”) developing innovative treatments for severe and resistant bacterial infections, announces the launch of a bidding process ( appel d’offres ) until April 11, 2025. The court-appointed administrator ( administrateur judiciaire ) has published a notice in the newspaper Les Echos (to be published on March 14, 2025) with a view to seeking potential buyers as part...

Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1) , a biopharmaceutical company (“ PHAXIAM ” or “ the Company ”) developing innovative treatments for severe and resistant bacterial infections, announces that, following the Company’s request, the Commercial Court of Lyon decided on March 6, 2025, to open a judicial receivership procedure. In an extremely challenging financing environment for biotech companies and listed small caps, and after several unsuccessful...

Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR001400K4B1) , has requested Euronext to suspend the trading of its stock listed on the Euronext Paris market from the publication of this press release, pending the release of an upcoming press release. About PHAXIAM Therapeutics PHAXIAM is a biopharmaceutical company developing innovative treatments for resistant bacterial infections, which are responsible for many serious infections. The company is building on an innovative approach...

Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135) , a biopharmaceutical company (“ PHAXIAM ” or “ the Company ”) developing innovative treatments for severe and resistant bacterial infections and Technophage SA (“ Technophage ”), a Portuguese company specializing in GMP phage development, today announces a strategic collaboration. This strategic partnership aims to provide physicians across Europe with access to a comprehensive GMP phages portfolio, enabling the...

Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM – FR0011471135 ), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its financial calendar for 2025. Financial calendar for 2025 1 Update on business and 2024 full-year financial results : press release on Thursday, March 13, 2025 (after market close), followed by a webinar in French at 6:00 pm CET, Annual General Meeting on Tuesday, June 24, 2025, Update on business...

Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces an update on its clinical data from patients treated with the Company’s phages under the compassionate status. Since 2017, PHAXIAM has treated more than 120 patients under Compassionate status, mostly suffering from hip or knee Prosthetic Joint Infections (PJI). The vast majority was treated in France...

Regulatory News: PHAXIAM (Paris:PHXM): Listing market: Euronext Paris (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) Website : www.phaxiam.com Date Total of shares composing the share capital Total of brut (1) voting rights Total of net (2) voting rights December 31, 2023 6 075 105 6 226 982 6 226 733 January 31, 2024 6 075 105 6 227 002 6 226 753 February 29, 2024 6 075 105 6 226 951 6 226 702 March 29, 2024 6 075 105 6 226 938 6 226 689 April 30, 2024 6 075 105 6 226 932 6 226 683...

Regulatory News: PHAXIAM Therapeutics (Euronext: PHXM - FR0011471135), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announced the clinical results of the PhagoDAIR I pilot study, demonstrating an excellent phage safety profile and a 74% infection control rate in the Phages arm for patients who received a single intra-articular injection, consistent with clinical data that observed in patients treated on a compassionate basis....